SCHEMBL22200345

SCHEMBL22200345

CC(C)n1c(=O)c(-c2ccc(NSCc3ccc(C#N)cc3)c(F)c2)nc2cnc(N)nc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.53
ALDH1A1 P00352 9/20 0.36
HSD17B10 Q99714 9/20 0.36
USP2 O75604 8/20 0.36
CYP3A4 P08684 8/20 0.36
CYP1A2 P05177 8/20 0.36
CASP1 P29466 6/20 0.36
CASP7 P55210 6/20 0.36
CYP2D6 P10635 4/20 0.36
HIF1A Q16665 2/20 0.36
MEN1 O00255 2/20 0.36
GLA P06280 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 2/20 0.36
CYP2C9 P11712 6/20 0.35
TP53 P04637 4/20 0.35
CYP2C19 P33261 3/20 0.35
LMNA P02545 1/20 0.35
NTRK1 P04629 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200603 0.91 ERN1 (0.43) ERN1ALDH1A1HSD17B10USP2CYP3A4
SCHEMBL22200338 0.90 ERN1 (0.41) ERN1ALDH1A1HSD17B10USP2CYP3A4
SCHEMBL22200361 0.86 ERN1 (0.45) ERN1ALDH1A1HSD17B10USP2CYP3A4
SCHEMBL25035430 0.86 ERN1 (0.69) ERN1ALDH1A1HSD17B10USP2CYP3A4
SCHEMBL22200583 0.85 ERN1 (0.54) ERN1ALDH1A1HSD17B10USP2CYP3A4
SCHEMBL22200356 0.84 ERN1 (0.41) ERN1ALDH1A1HSD17B10USP2CYP3A4
SCHEMBL22200353 0.82 ERN1 (0.40) ERN1ALDH1A1HSD17B10USP2CYP3A4
SCHEMBL22200355 0.82 ERN1 (0.41) ERN1ALDH1A1HSD17B10USP2CYP3A4
SCHEMBL22200589 0.81 ERN1 (0.46) ERN1ALDH1A1HSD17B10USP2CYP3A4
SCHEMBL22200788 0.81 USP2 (0.40) ERN1ALDH1A1HSD17B10USP2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed